Evaluation of clINical reCovery After a Relapse: a Pilot Study assEssing the Neuronal Effects of D-Aspartate in RR-MS Subjects Treated With IntErferon Beta 1a 44 mcg TIW (INCREASE)
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 02 Jan 2019
At a glance
- Drugs Interferon beta-1a (Primary) ; Methylprednisolone
- Indications Multiple sclerosis
- Focus Therapeutic Use
- Acronyms INCREASE
- Sponsors Merck KGaA
- 21 Dec 2018 Planned End Date changed from 25 Dec 2018 to 4 Jan 2019.
- 21 Dec 2018 Planned primary completion date changed from 25 Dec 2018 to 4 Jan 2019.
- 26 Sep 2018 Planned End Date changed from 30 Jun 2020 to 25 Dec 2018.